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Abstract
Background: Staphylococcus aureus is a commensal of human skin and nares. It is also one of the leading
nosocomial pathogens in both developed and developing countries and is responsible for a wide range of life
threatening infections, especially in patients who are immunocompromised, post-surgery, undergoing
haemodialysis and those who are treated with catheters and ventilators. Over the past two decades, the incidence
of nosocomial staphylococcal infections has increased dramatically. Currently there are at least seven vaccine and
immunotherapy candidates against S. aureus in the developmental phase targeting both active and passive
immunization.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was
done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against
Staphylococcus aureus relevant to several criteria of interest: answerability; cost of development, production and
implementation; efficacy and effectiveness; deliverability, affordability and sustainability; maximum potential impact
on disease burden reduction; acceptability to the end users and health workers; and effect on equity. In Stage II,
we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health
researchers, international policy makers and representatives of pharmaceutical companies) to participate. The policy
makers and industry representatives accepted our invitation on the condition of anonymity, due to sensitive nature
of their involvement in such exercises. They answered questions from CHNRI framework and their “collective
optimism” towards each criterion was documented on a scale from 0 to 100%.
Results: The panel of experts expressed low levels of optimism (score around or below 50%) on the criteria of
answerability, efficacy, maximum disease burden reduction potential, low cost of production, low cost of
implementation and affordability; moderate levels of optimism (scores around 60 to 80%) that these vaccines could
be developed at a low cost, and thus on the deliverability, sustainability and impact on equity; and high levels of
optimism (scores above 80%) regarding acceptable of such a product to both the end-users and health workers.
While assessing the candidates for passive immunization against S.aureus, the experts were poorly optimistic
regarding low production cost, low implementation cost, efficacy, deliverability, sustainability, affordability and
equity; moderately optimistic regarding answerability and acceptability to health workers and end-users. They were
of the opinion that these interventions would have only a modest impact (3 to 5%) on the burden of childhood
pneumonia.
Conclusion: In order to provide an effective vaccine against S. aureus, a number of unresolved issues in vaccine
development relating to optimal antigenic target identification, criteria for acceptable efficacy, identification of
target population, commercial development limitations, optimal timing of immunization strategy, storage, cold
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any medium, provided the original work is properly cited.chain requirements and cost need to be addressed properly. There is still a great deal unknown about the
complex interaction between S. aureus and the human host. However, given the nature of S. aureus and the
lessons learned from the recent failure of two emerging vaccines, it is clear that a multi-component vaccine is
essential. Combating only one virulence factor is not sufficient in the human host but finding the right
combination of factors will be very challenging.
Background
Pneumonia is the leading cause of global child mortality.
Approximately 1.6 million children under the age of
5 years die each year due to pneumonia [1]. Most pro-
spective aetiology studies of pneumonia suggest that
Streptococcus pneumoniae (pneumococcus) and Haemo-
philus influenzae type b (HiB) are the leading bacterial
causes followed by Staphylococcus aureus (Staphylococ-
cus) and Klebsiella pneumoniae. Though effective vac-
cines exist against the two major causes of bacterial
pneumonia, no vaccine is presently available against
S. aureus.
Staphylococcus aureus is a Gram-positive bacterial
commensal of human skin and nares. About 20-30% of
the human population are S. aureus carriers and show
little resistance to mucosal colonization by the pathogen
[2,3]. Colonization may be transient or persistent and
can last for years [4]. Staphylococcus aureus is also one
of the leading nosocomial pathogens in both developed
and developing countries, causing infection frequently in
immunocompromised patients, surgical patients,
patients undergoing haemodialysis and those who are
treated with catheters and ventilators [2]. In the past 20
years the incidence of nosocomial staphylococcal infec-
tions has increased dramatically. It is now responsible
for approximately 25% of the 2 million nosocomial
infections reported in the United States each year [5]. In
addition, the increasing trend of methicillin-resistant S.
aureus (MRSA) infection has posed new problems.
MRSA is now endemic in hospitals around the world
with an estimated 1.5 million cases per year worldwide
[6,7]. The incidence of community-acquired MRSA
infections are also increasing and there are reports of
MRSA strains with reduced susceptibility to Vancomy-
cin [8-11]. This establishes a need for new treatment
and prevention strategies against S. aureus.
Vaccine development needs extensive research and
resources. The development of Staphylococcal vaccine is
further complicated by the pleomorphic character of sta-
phylococci and complex patient populations at risk. The
target population for S. aureus vaccination is different
from other vaccines against pneumonia. In order to pro-
vide a full range of protection both active and passive
immunization approaches need to be taken. An active
immunization strategy may be a feasible approach for pre-
venting staphylococcal infections in immunocompetent
patients scheduled to undergo elective procedures. Popula-
tions at high risk for S. aureus infections, where active
immunization is unlikely to be helpful, include neonates,
especially premature newborns; other more completely
immunocompromised children (e.g., certain cancer
patients on immunosuppressive therapy); and populations
where the risk of infection is both high and immediate
(e.g., shock-trauma patients). One approach to providing
these individuals with immunoprophylaxis is to use these
vaccines as immunizing agents in healthy adult plasma
donors, collect their plasma, and then fractionate it to pro-
duce specific hyper-immune gamma immunoglobulin
(IGIV) for intravenous passive immunization. It should be
noted that for some patients, such as those receiving pros-
thetic devices e.g. hip replacements, it may be necessary to
provide both passive and active immunization in order to
protect the individual from infection immediately after
surgery and in the longer term.
It is therefore very important to assess the potential
impact of all emerging vaccines and immunotherapy
against Staphylococcus aureus and determine an invest-
ment strategy based on key prioritization factors. Cur-
rently there are at least seven products against S. aureus
in the developmental phase targeting both active and
passive immunization. We aimed to review the existing
literature, outlining the progress of the emerging vac-
cines and immunotherapy against Staphylococcus aureus
at all stages of development; present the evidence
regarding key issues surrounding these products and
assess the level of collective optimism of international
experts over their priority status for receiving invest-
ment support. The paper is presented as part of a series
o fp a p e r s ,e a c hi nt u r nf o c u s i n go nd i f f e r e n te m e r g i n g
vaccines and other interventions against pneumonia.
Methodology
We used a modified Child Health and Nutrition
Research Initiative (CHNRI) methodology for setting
priorities in health research investments. The methodol-
ogy has been described in great detail [12-16] and
implemented in a variety of settings [16-22].
CHNRI exercise – stage I: identification and selection of
studies
We conducted a systematic literature review using the
following criteria: answerability, cost of development,
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effectiveness, deliverability, affordability, sustainability,
maximum potential impact on disease burden reduction,
acceptability to health workers, acceptability to end
users and equity [19] (Figure 1). Searches were con-
ducted initially in July 2009 (and updated in April 2010)
and were limited to Ovid MEDLINE, Web of Knowl-
edge, Google Scholar and Cochrane central register for
controlled trials. No language or publication restrictions
were applied. In order to ensure completeness, we also
conducted hand searching of online journals, scanned
the reference list of identified citations, and checked lit-
erature available on the websites of pharmaceutical
companies (Inhibitex Inc., Merck, Nabi Biopharmaceuti-
cals, Neutec Pharma Ltd. and Biosynexus) and interna-
tional agencies (GAVI, WHO, UNICEF and Pneumo
ADIP). Details of the search strategies used are pre-
sented in Additional file 1.
CHNRI exercise – stage II: an expert opinion exercise
We shared the initial review of the literature with 20
experts. The list of chosen experts included five leading
basic scientists, five international public health research-
ers, five international policy makers and five representa-
tives of the pharmaceutical companies. The 20 experts
were chosen based on their excellent track record in
child health research (but were not specifically involved
with staphylococcal disease research). We initially
offered participation to the 20 experts with the highest
impact publications in their area of expertise over the
past 5 years (for basic researchers and international pub-
lic health researchers), or to individuals who were
affiliated with pharmaceutical companies that had large
vaccination programmes or working in large-budget
international agencies. For those who declined to parti-
cipate (about 20%) replacements were found using the
same criteria. The policy makers and industry represen-
tatives accepted our invitation on the condition of anon-
ymity, due to sensitive nature of their involvement in
such exercises. About half of the experts were either
affiliated to institutions in developing countries or had
previous experience of working in developing country
settings. The experts met during September 7-13, 2009
in Dubrovnik, Croatia, to conduct the 2
nd stage of
CHNRI expert opinion exercise. The process of second-
stage CHNRI is shown in Figure 2. All invited experts
discussed the evidence provided in CHNRI stage I, and
then answered questions from the CHNRI framework
(Supplementary table 2 in additional file 1). Their
answers could have been “Yes” (1 point), “No” (0
points), “N e i t h e rY e sn o rN o ” (0.5 points) or “Don’t
know” (blank). Their “collective optimism” towards each
criterion was documented on a scale from 0 to 100%.
The interpretation of this metric for each criterion is
simple: it is calculated as the number of points that
each evaluated type of emerging intervention against
Staphylococcus aureus received from 20 experts (based
on their responses to questions from the CHNRI frame-
work), divided by the maximum possible number of
points (if all answers from all experts are “Yes”). [12-16].
Results
We identified 63 articles andp r o d u c tm o n o g r a p h sf o r
inclusion. Several products are currently in development
phase, most of which have completed phase I and II
clinical trials (Figure 3 and Figure 4). Each product tar-
gets different virulence factors of the S. aureus patho-
gen. These factors include Staphylococcal surface
proteins, polysaccharides, exoproteins and toxins elabo-
rated by S. aureus. The only product which completed a
Phase III clinical trial is Aurograb. Aurograb was a
human-derived single chain variable fragment (scFv)
therapeutic antibody against the S. aureus ATP-binding
cassette (ABC) transporter. Aurograb was developed for
the treatment of deep-seated MRSA infections. In 2006,
the product completed a double-blind placebo-con-
trolled phase III clinical trial carried out in a total of 35
centres in 6 European countries. However in 2008 the
company decided not to pursue further development of
Aurograb. The potential impact of Aurograb will not be
assessed in this paper.
Answerabilty
Active immunization
CP5 /CP8 Conjugate vaccines (StaphVAX, PentaS-
taph) Bacterial capsular polysaccharides (CPs) confer
resistance against host immune mechanisms and pro-
mote virulence. Antibodies to these CPs were shown to
protect against infections caused by pneumococci,
meningococci, Haemophilus influenzae type b and other
pathogens. S. aureus isolates were initially believed not
to possess capsular polysaccharides. However, Karakawa
and colleagues discovered that S. aureus clinical isolates
are capsulated and similar to pneumococci and group b
Streptococci in that they posses several different capsular
types [23]. They also showed that conjugate vaccines to
these polysaccharides generate antibodies that mediate
type-specific opsonophagocytosis in an in vitro opsono-
phagocytic assay that contained complement and neu-
trophils [24]. Of the 13 known serotypes, two capsular
types, 5 and 8, are the most important as they comprise
the majority (~85%) of clinical isolates [9,25,26]. Fattom
and colleagues combined the capsular polysaccharide 5
and capsular polysaccharide 8 to the mutant non toxic
recombinant Pseudomonas aeruginosa exotoxin A
(rPEA) and formed the bivalent vaccine StaphVAX [27].
Iron regulated surface determinant B (V710) The
potential of surface proteins of gram positive bacteria as
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criteria). CHNRI- Child Health and Nutrition Research Initiative.
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the case of S. aureus, none of the surface proteins that
were tested as an antigen were found to be essential
components of the pathogen. There is a high level of
redundancy in the virulence protein range. Such redun-
dancy makes the loss of a specific protein non fatal in S.
aureus. Iron regulated surface determinant B (IsdB), an
iron-sequestering protein, is conserved in diverse S. aur-
eus clinical isolates, both methicillin resistant and methi-
cillin sensitive. IsdB is expressed when there is iron
limitation and has a role in the acquisition of iron [28].
IsdB was first identified as a candidate antigen by Etz and
colleagues [29]. It has been reported that although IsdB is
not an essential protein for S. aureus in vitro and loss of
this protein results in a reduction in virulence in vivo,
which makes it an attractive vaccine candidate [28].
Merck`s new vaccine V710 contains IsdB protein antigen.
Presented with this evidence, the panel of experts
expressed a low level of optimism (score around 40%)
regarding the ability of vaccines for active immunization
against S. aureus to satisfy the criterion of answerability
(Figure 5).
Figure 2 A summary of Stage II of the CHNRI process of evaluation of an emerging intervention (an expert opinion exercise using the
CHNRI criteria). CHNRI- Child Health and Nutrition Research Initiative.
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S. aureus Clumping factor A- based vaccines (Vero-
nate and Aurexis ) Staphylococcus aureus colonizes the
host by adhering to components of the extra cellular
matrix through surface protein adhesions known as
microbial surface components recognizing adhesive
matrix molecules (MSCRAMM) [30]. MSCRAMM bind
to extracellular matrix components within host tissues
or to serum-conditioned implanted biomaterials (e.g
catheters, artificial joints, and vascular grafts). Evidence
s u g g e s t st h a tt h i sm i c r o b i a la d h e r e n c ei sa ni m p o r t a n t
factor in the initiation and metastatic spread of S. aur-
eus infections [31]. Therefore, interventions that impact
on early events in the infectious process may lead to an
improved clinical outcome. MSCRAMMs have therefore
been targeted as potential antigenic candidates for the
development of novel immunotherapies. One such
MSCRAMM protein is Clumping factor A (ClfA), an
adhesin that mediates S. aureus binding to fibrinogen. It
is expressed on the surface of almost all strains of S.
aureus[8]. ClfA recognizes the C terminus of the g chain
of human fibrinogen [29,30,32] and antibodies raised
against the A domain of ClfA can inhibit the interaction
b e t w e e nC l f Aa n df i b r i n o g e n .B a s e do nt h i s ,I n h i b i t e x
developed INH-A21 (Veronate), which is a human intra-
venous immune preparation derived from donors with
high levels of antibodies against the staphylococcal fibri-
nogen binding proteins ClfA and Ser-Asp dipeptide
repeat G (SdrG).
Another similar product in the pipeline that is also
being developed for the treatment of serious S. aureus
bacteremia and related complications is Tefibazumab
(Aurexis) [33]. This is a humanized immunoglobulin G1
monoclonal antibody that specifically recognizes ClfA
with a high affinity.
Hyper immunoglobulin from patients immunuized
with CP5 /CP8 Conjugate vaccines (AltaStaph) A par-
allel track for developing immunotherapy against S. aur-
eus was developed concurrently to the development of
the StaphVAX. This approach utilized the vaccine to pro-
duce hyper-immune IgG for the treatment of patients at
high risk for S. aureus infections that could not mount a
significant immune response to the vaccine, or to be used
as an adjunct therapy in patients who are already infected
with S. aureus. Plasma donors were immunized once
with StaphVAX and plasma were collected at least once a
week starting two weeks after immunization. Plasma
pools were made and IgG was fractionated using the
Cohn fractionation technique. The purified IgG was for-
mulated as intravenous immunoglobulin preparation
(IVIG) at 50mg/ml IgG. The types 5 and 8 CP antibodies
comprised up to 6% of the total IgG.
Chimeric monoclonal antibody (Pagibaximab) Lipo-
teichoic acid (LTA) is a major constituent of the cell
wall of gram positive bacteria and consists of teichoic
acids, which are long chains of ribitol phosphate and
glycerolipid. Available evidence suggests that LTA pos-
sess antigenic properties. Biosynexus has developed a
humanized mouse chimeric mAB agaistt LTA called
pagibaximab (BSYX – A 1 1 0 ) .T h ea n t i b o d yi st a r g e t e d
at low birth weight infants for the prevention of blood
stream infections by S. aureus and coagulase negative
staphylococci [34].
Although not supported by hard evidence, the panel of
experts expressed moderate levels of optimism (median
score around 60 percent, which was greater than for
active immunization) concerning the ability of immu-
notherapy for passive immunization to satisfy the criter-
ion of answerability (Figure 6).
Pre-clinical P I Phase II Phase III Phase IV
Failed Phase III
By Nabi
StaphVax
(Bivalent CP5&CP8 
conjugate) Phase II
By Merck:
V710-0657nl
(Antigen Target: IsdB)
Current Status: Active Immunisation
After unsatisfactory phase III, Nabi
developed TriStaph (Trivalent CP5, 
CP8 & 336), and further developed 
PentaStaph (additional of 2 other 
components) 
In Aug 2009, GSK acquired the 
PentaStaph program 
Figure 3 The current status of the research into Staphylococcal
vaccines presented to the expert group for stage II of the
CHNRI process.
Pre-clinical P I Phase II Phase III Phase IV
Failed Phase III
By Inhibitex:
Veronate
(INHA-21: mAb against 
ClfA and SdrG)
Phase II
By Inhibitex: 
Aurexis
(Tefibazumab: mAb
against Clf A)
Entering Phase IIb/III in 2009
By Biosynexus: 
Pagibaximab
(BSYX-A110: mAb against 
targeting LTA) 
Current Status: Passive Immunisation
Phase II
By Nabi: 
Alfastaph
(Hyper-immune IgG
against CP5 and 
CP8)
Figure 4 The current status of the research into passive
immunization against S. aureus presented to the expert group
for stage II of the CHNRI process.
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Active immunization
CP5 /CP8 Conjugate vaccines (StaphVAX, TriStaph,
PentaStaph) The first phase III clinical study of the
StaphVAX vaccine conducted on 1804 haemodialysis
patients showed mixed results [35]. Although the study
population comprised of extremely immunocompromised
patients, the vaccine elicited antibody response levels of at
least 80 µg per millilitre (the estimated minimal protective
level) in 80% of patients for CP5 and in 75% of patients for
CP8. However, the efficacy was not sustained. The efficacy
during weeks 3 to 54 was only 26%.
Vaccines against S. Aureus
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Figure 5 The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
staphylococcal vaccines. CHNRI- Child Health and Nutrition Research Initiative.
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that capsular antibodies can afford protection against S.
aureus infections. However, in these severely immuno-
compromised patients a different regimen that can sus-
tain high levels of antibodies beyond one year is needed.
A confirmatory Phase III clinical trial with 3600 haemo-
dialysis patients was conducted and included a booster
immunization at 8 months following the first immuniza-
tion. The confirmatory phase III study reported no sig-
nificant protection against S. aureus. The failure was
attributed to slight changes in manufacturing that
resulted in a suboptimal antibodies generated by the
vaccine. A press release by Nabi (http://www.nabi.com)
dated 21 March 2006 stated : “The quality or functional
Passive immunization against S. Aureus
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Box-and-Whisker plot of the experts' score
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For Max Burden Reduction: Median (IQR): 5% (1, 5%), min: 0%, max: 50% 
Figure 6 The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
passive immunization against S.aureus. CHNRI- Child Health and Nutrition Research Initiative.
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used in the confirmatory clinical study was inferior to
those antibodies generated by vaccine lots used in pre-
vious and subsequent clinical studies”. We found no
report on further study of StaphVAX.
The clinical outcome from these studies and other
animal model studies suggests that capsular polysacchar-
ides are appropriate for generating protective opsonic
antibodies. However, more antigens are need to be
added to extend the coverage of the vaccine and to neu-
tralize significant toxins that debilitate host immune
competency.
Nabi added three more components to their original
StaphVAX formula to form the five component vaccine
PentaStaph [36,37]. The new surface polysaccharide
component, 336, induces antibodies against Type 336
cell wall antigen while the other two candidate compo-
nent generates antibodies that neutralize Panthon
Valentine Leukocydin, PVL, a unique leukocidin toxin,
produced by the CA-MRSA strains and alpha toxin pro-
duced by almost all S. aureus isolates; both these debili-
tate host immune competency including the
opsonophagocytosis process.
In August 2009 GSK acquired the PentaStaph pro-
gram from Nabi and are currently undertaking its
further development. [http://www.nabi.com/pipeline]
Iron regulated surface determinant B (V710) The vac-
cine was found to be immunogenic in an animal model
when it was formulated with amorphous aluminum
hydroxyphosphate sulfate adjuvant. Three phase I stu-
dies were conducted to evaluate different formulations
(Liquid Aluminum –adjuvanted, Liquid non adjuvanted,
and lyophilized) of V710 vaccine [28,38]. The results of
the studies showed similar immunogenecity with all for-
mulations. A positive immune response, as defined by
more than a two fold increase in antibody levels, ranges
from 72% to 84% across different formulations. No ser-
ious side effects or fever were reported. The most com-
mon vaccine related adverse effects were pain at
injection site and headache [38]. Phase II clinical trials
are currently underway to evaluate the efficacy and
safety of a single dose of the vaccine in patients under-
going elective cardiothoracic surgery and to assess the
safety and immunogenicity of the vaccine candidate in
patients with end-stage kidney disease who are receiving
hemodialysis. A randomized, multicenter, double-blind,
group-sequential study to evaluate the efficacy, immuno-
g e n i c i t y ,a n ds a f e t yo fas i n g l ed o s eo fV 7 1 0i na d u l t
patients scheduled for cardiothoracic surgery is currently
underway (http://clinicaltrials.gov/ct2/show/
NCT00518687). It is too early to judge the efficacy of
the new vaccine.
Based on this limited evidence, the panel of experts
expressed a relatively low level of optimism (score
around 40%) concerning the likelihood of efficacy of
vaccines for active immunization against S. aureus to
reduce childhood pneumonia mortality (Figure 5).
Passive immunization
S. aureus Clumping factor A- based vaccines (Vero-
nate and Aurexis ) A multicenter double blind study
was conducted in infants with very low birth weight to
assess the safety profile and efficacy of INH-A21[39].
Infants were randomized to three different dose groups
(250, 500 or 750 mg/kg). The INH-A21 750 mg/kg
group (N = 157) reported fewer episodes of Staphylococ-
cus aureus sepsis [RR=0.37; P = 0.14], candidemia
(RR=0.34; P = 0.09) and mortality (RR=0.64; P = 0.27)
when compared with the placebo-treated cohort (N =
158). A follow up phase III double blinded placebo con-
trolled study [40] was conducted with 1983 infants to
retest the safety and efficacy of INH-A21. The primary
outcome measure was the rate of S. aureus associated
late-onset sepsis (LOS) which developed in 5% and 6%
of infants who received the placebo or INH-A21 respec-
tively (P = 0.34). Disappointingly, no differences were
found in the frequencies of LOS, candidemia, or overall
mortality in the two groups. However, Schaffer and Lee
in their review of vaccines against S.aureus suggested [8]
that as the INH-A21 product was not elicited by immu-
nization but instead by natural exposure to staphylo-
cocci, it is possible that the antibodies might have
recognised the wrong ClfA epitopes or may have been
of low affinity or avidity towards their target antigens.
An adequately powered, well-controlled study was
recommended to further assess the efficacy and safety of
INH-A21.
A randomized, double-blind, placebo-controlled, mul-
ticenter phase II clinical trial was conducted in hospita-
lised patients with documented S. aureus bacteraemia
[29] to evaluate the efficacy of Tefibazumab (Aurexis).
The efficacy was assessed in terms of relapse of S. aur-
eus bacteraemia (SAB), complications related to S. aur-
eus bacteraemia, or death. Two of 30 (6.7%) patients
reached the composite clinical endpoint in the Tefibazu-
mab group while for the placebo group the number was
4 out of 30 (13.3%) (P = 0.455). However, several limita-
tions in this study were reported with respect to out-
comes. There were differences in baseline characteristics
of the study populations and the use of antibiotic in the
protocol was not standardized. Moreover, adjunctive
treatments, such as surgery and timing of catheter
removal, were not taken into consideration in the study
analysis. The most frequently reported adverse events
were hypokalemia, diarrhea, anemia, and insomnia but
t h e r ew e r en os i g n i f i c a n td i fferences across the treat-
ment groups. As expected for a group of patients with
SAB, twelve (40%) patients in the Tefibazumab group
and nine (30%) patients in the placebo group had at
Huda et al. BMC Public Health 2011, 11(Suppl 3):S27
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this clinical trial and preliminary clinical data support
continued clinical development. More trials are needed
to evaluate efficacy of this product.
Hyper immunoglobulin from patients immunized
with CP5 /CP8 Conjugate vaccines (AltaStaph) A
multicenter Phase 2 clinical trial to assess the safety and
pharmacokinetics of AltaStaph in very low birth weight
(VLBW) infants was performed. Neonates were infused
twice in two weekly intervals with saline or AltaStaph at
1000mg/kg. Levels for CPS types 5 before the second
infusion were 188 mcg/ml. Type 8 IgG levels were simi-
lar. Geometric mean IgG levels among placebo recipi-
ents were consistently <2 and <5 mcg/ml for types 5
and 8 respectively in both weight groups. The conclu-
sion from this study was that infusion of AltaStaph in
VLBW neonates resulted in high levels of specific S.
aureus types 5 and 8 CPS IgG. The administration of
this anti-staphylococcal hyperimmune globulin was well
tolerated in this population [41]. Since the study was
not powered to detect clinical outcomes, the data gener-
ated did not show differences in the rate of S. aureus
infection between the two study arms.
In another study in adults with culture proven bactere-
mia, AltaStaph was evaluated as a potential adjunctive
therapeutic in adult subjects with S. aureus bacteremia
and persistent fever. Administration of AltaStaph had a
positive effect on the APACHE II scores of these patients
compared to patients who received the placebo treat-
ment. This was further supported by the time to hospital
discharge. For all subjects, the median time to discharge
excluding deaths that occurred during hospitalization,
which could bias the results, were 14 and 9 days in the
placebo and AltaStaph groups respectively (P=0.033). It
was concluded that AltaStaph was shown to be well tol-
erated in subjects with S. aureus bacteremia and war-
ranted further evaluation as an adjunct therapy against
multidrug resisitant S. aureus bacteremia [42].
Chimeric monoclonal antibody (Pagibaximab) A
phase I/II dose escalation, safety and pharmacokinetics
study of Pagibaximab was conducted and the findings
showed no difference in morbidities and mortality
across study groups. All serious adverse effects were
deemed unrelated or probably not related to the drug.
However, no evidence of a response to Pagibaximab was
detected [43]. Another phase II randomized double-
blind study of Pagibaximab in very low birth weight
neonates concluded that three infusions of Pagibaximab
60 or 90 mg/kg, administered 1 week apart to high-risk
neonates, appeared safe, well tolerated, demonstrated
linear pharmacokinetics, and at 90 mg/kg produced
potentially protective levels of antibody [44].
Based on these evidence, the panel expressed a low
level of optimism (score around 30 percent) regarding
the likelihood of efficacy of immunotherapy for passive
immunization against S. aureus.
Maximum potential for disease burden reduction
Rudan et al. [45] estimated that the incidence of clinical
pneumonia in under 5 children in developing countries
was about 0.29 episodes per child year or 151.8 million
new cases every year. In contrast, the number of new
cases per year in developed countries was estimated to
be around 4 million. The Child Health Epidemiology
Reference Group (CHERG) estimated that around 1.6
million deaths in under five children were attributable
to pneumonia in 2008 [1].
Results from prospective microbiology-based pneumo-
nia etiology studies revealed that the leading bacterial
cause for pneumonia is pneumococcus (isolated in 30–
50% of pneumonia cases) while the second most com-
mon isolated pathogen was H. influenzae type b. Staphy-
lococcus aureus w a si d e n t i f i e da st h et h i r dm o s t
common bacterial cause [46-53]. A study in Chile using
lung aspirate cultures found S. aureus to be the main
pathogen [54]. Another WHO study of hospitalised chil-
dren with very severe pneumonia in seven countries
found S. aureus in 42% of cases making it the second
largest cause [32]. Studies of nosocomial pneumonia
and ventilator associated pneumonia have demonstrated
that S. aureus was responsible for majority of the cases
[55,56]. Furthermore, MRSA has been identified as one
of the most common pathogens in all forms of pneumo-
nia [57]. In recent years, the HIV epidemic has also led
to an increase in the incidence and mortality from child-
hood pneumonia. Although there are limited data on
the causes of neonatal pneumonia in developing coun-
tries, studies on the aetiology of neonatal sepsis suggest
Klebsiella spp., Group B Streptococcus and S. aureus are
the main causes of neonatal pneumonia [58].
Developing an effective vaccine would result in a sig-
nificant reduction of disease burden from S. aureus
infections. However, quantification of the maximum
reduction of disease burden using the staphylococcus
vaccines without any information on the burden of dis-
ease from S. aureus pneumonia and studies on vaccine
effectiveness is not possible. None of the vaccine candi-
dates have passed phase III trials. The major problem
with developing staphylococcal vaccines is the lack of
understanding of how virulence factors or potential anti-
g e n sa r ee x p r e s s e db yb a c t e r i ai nt h eh o s tv e r s u st h o s e
that have been studied in vitro. However, given the
pleomorphic nature of the pathogen and the failure of
single component vaccines, it is anticipated that without
a multi-component vaccine a significant reduction of
disease burden will not be possible [8].
The panel was of the opinion that both types of
immunizations against S. aureus were likely to have a
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on disease burden due to childhood pneumonia (Figure
5 and Figure 6).
Deliverability, affordability, sustainability and cost
Deliverability and sustainability of any new vaccine strat-
egy depends on the infrastructure and resources
required to deliver the vaccine. Most of the vaccines
need cold storage facilities. In many developing coun-
tries the cold chain system is breaking down. A study in
Ethiopia found 31% of the equipment to be non-func-
tional, with a large number of items having exceeded
the manufacturer’s recommended working life [59]. So a
heat stable S. aureus vaccine could achieve a high cover-
age even in the hard to reach areas of the developing
countries. However, we were unable to find any reports
which would suggest that the candidate vaccines pre-
sently under development are using technology that can
retain the potency and efficacy at elevated temperatures.
S t o r a g ei sa n o t h e rk e yi s s u ew h i c hn e e d st ob et a k e n
into consideration while designing any vaccination pro-
gram. The newer vaccines are often single-dose presen-
tation in pre-filled glass syringes and bulky packaging
which need more storage space. Although none of the
staphylococcal vaccines are ready for licensure at this
point of time, manufacturers will need to take these fac-
tors into consideration while designing the packaging
for the newer vaccines.
As discussed earlier, an effective staphylococcal vacci-
nation strategy will require quite a different immuniza-
tion program and this is likely to increase the
complexity of vaccine delivery mechanism in developing
countries. Some have advocated that if an effective vac-
cine is developed it should be used in all children to
prevent any type of staphylococcal disease. The recent
increase in community-associated MRSA in children
with no predisposing risk factors e.g. healthy newborns
and young adults, and increase in the prevalence of S.
aureus colonization in the general population support
such argument [60]. However, it will remain a challenge
to develop a staphylococcal vaccine that would be cross
protective against multiple strains as well as strains
which are of the same serotype but express antigens dif-
ferently under the same conditions.
Another important factor determining the deliverabil-
ity of a vaccine is cost. However, different initiatives
have emerged recently to help the uptake of newer vac-
cines by developing countries. In 2007, WHO and
PATH, with the support of the Bill & Melinda Gates
Foundation, launched Optimize – a global effort to help
countries manage immunization logistics. The Interna-
tional Finance Facility for Immunisation (IFFIm), a mul-
tilateral development institution, has been created to
accelerate the availability of predictable long term funds
for health and immunization programmes through the
GAVI Alliance in 70 of the poorest countries in the
world. Another similar initiative is Advance Market
Commitment (AMC). Established in 2005 by the Center
for Global Development and carried forward by five
bilateral donor governments, the Bill & Melinda Gates
Foundation, the GAVI Alliance, and the World Bank,
the AMC aims to stimulate the development and manu-
facture of vaccines especially suited to developing coun-
tries. With the help of these initiatives it is hoped that
the time delay between the introduction of new vaccines
into developed and developing countries can be reduced.
Based on all available evidence the expert group
expressed a moderate level of optimism (score about
60%) in the ability to develop a low cost intervention for
active and passive immunizations against staphylococcus
(Figure 5 and Figure 6). However, they expressed low
levels of optimism (scores below 40%) that these inter-
ventions would have low production and implementa-
tion costs, which would have a direct impact on
affordability, deliverability (more for passive immuniza-
tion) and sustainability.
Acceptability and equity
While assessing the impact of a new intervention on
child health equity, the panel considered the following
questions: given the present distribution of the disease
burden from S. aureus infections, will the intervention
be accessible to the underprivileged in the population
and would it benefit them? And does the proposed
research have the overall potential to improve equity in
disease burden distribution in the long term?
Little information is available regarding the burden of
disease from S. aureus infections in developing countries.
It is therefore difficult to assess whether a staphylococcal
vaccine will have a relatively greater impact on the poor-
est communities in the world. Studies which include new
molecular techniques are required to provide a better
knowledge base about the burden of disease from staphy-
lococcus pneumonia in developing countries.
The panel of experts expressed a moderate level of opti-
mism (score about 60 percent) over the impact of staphy-
lococcal vaccines on equity compared to interventions for
passive immunization (score about 40 percent). However,
the panel was very optimistic (scores above 80%) that if
such a vaccine were to be developed it would be accepta-
ble to both end-users and health workers (Figure 5). They
were only moderately optimistic (scores about 70%)
regarding the acceptability of passive immunization
against S.aureus to both health workers and end-users.
Discussion
The literature review summarized in this paper presents
evidence required for making an informed decision on
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interventions against S. aureus. The scores for both
active and passive immunization interventions against
the set criteria represent the collective optimism of a
panel of experts drawn from varying technical back-
grounds and affiliations. Although several S. aureus vac-
cine candidates are currently in pre-clinical and clinical
phases of development, none have yet been approved
for licensure. The development of S. aureus vaccines has
the potential to reduce the global burden of Staphylo-
coccal pneumonia. However, a number of unresolved
issues in S. aureus vaccine development need to be
addressed properly in order to develop a successful vac-
cination strategy [8]. There is little evidence that sup-
ports the argument that immunity to S. aureus infection
does indeed exist. It is also clear that S. aureus has
developed the capability to defend itself against human
innate immunity [61]. Imperfect animal models and the
recent failure of two candidate vaccines at Phase III
clinical trials has made the development process more
risky and complicated.
While the collective optimism of the panel regarding
vaccines against S. aureus on the CHNRI criteria was
low on answerability, efficacy, maximum disease burden
reduction potential, low cost of production, low cost of
implementation and affordability; they were moderately
optimistic that these vaccines could be developed at a
low cost, and thus on the deliverability, sustainability
and impact on equity; and highly optimistic that if such
an intervention were to be developed, it would be highly
acceptable to the end-users and health workers. While
assessing the candidates for passive immunization
against S.aureus, the experts were poorly optimistic
regarding low production cost, low implementation cost,
efficacy, deliverability, sustainability, affordability and
equity; moderately optimistic regarding answerability
and acceptability to health workers and end-users. They
were of the opinion that these interventions would have
only a modest impact (3 to 5%) on the burden of child-
hood pneumonia.
This is the first time that such an exercise has been
conducted with the aim of predicting the future impact
of emerging vaccines on morbidity and mortality due to
childhood pneumonia. The CHNRI methodology was
primarily designed to evaluate existing interventions and
competing investment priorities for health research.
Although we used the CHNRI set of criteria, we modi-
fied it by including a systematic review of available lit-
erature and not involving all stakeholders (e.g. end-users
and health workers). The scores reported in this paper
express the collective opinion of a panel of 20 experts.
While there is always an element of error while predict-
ing the impact of interventions which do not exist and
have no clinical trial data to support them, we feel that
the results would be reproducible with another panel in
a different setting.
Conclusions
To summarize, while it is not only important that
investments are made in researching new vaccines, ade-
quate emphasis must be made and resources allocated
for proper distribution of the vaccine. Additionally,
there are issues relating to optimal antigenic target iden-
tification, criteria for acceptable efficacy, identification of
the target population in children as well as adults, com-
mercial development limitations, optimal timing of
immunization strategy, storage and cold chain require-
ments, cost of development and cost effectiveness (64).
There is still a great deal unknown about the complex
interaction between S. aureus and the human host. All
vaccine candidates that have been tested so far were
found to play important roles in vivo. However, none of
these candidates have been found to be essential and
this raises the concern that making vaccines against
antigens that are not expressed in the host might lead
to ineffective vaccines. Given the nature of S. aureus
and the lessons learnt from the recent failure with two
emerging vaccines, it is clear that a multi-component
vaccine is essential. Combating only one virulence factor
is not sufficient in the human host but finding the right
combination of factors will be very challenging.
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